ArticleFrontiers in immunology2024

Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study.

Yushan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.